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a-Endorphin and y-endorphin, two closely related peptides of the pro-opiomelanocortin family with 
characteristic biological activities, were purified to homogeneity from single human pituitary glands and 
chemically identified. Isolation of the peptides was based on size fractionation by Sephadex G-75 
chromatography followed by two HPLC steps using reverse-phase and paired-ion reverse-phase systems 
and was monitored by radioimmunoassay. During the isolation procedure (Y- and r-endorphin-sized 
material behaved chromatographically and immunologically indistinguishably from synthetic (Y- and y- 
endorphin. The amino acid composition and NHZ-terminus of isolated peptides demonstrated their identity 
as authentic cy-endorphin and y-endorphin. Acetylated forms were absent. In addition, evidence is 
provided that large forms with LY- and y-endorphin immunoreactivity detected during gel filtration are 
human lipotropin-(l-74) and -(l-75), respectively. The data substantiate that cY-endorphin and y- 
endorphin exist as endogenous peptides in the human pituitary gland. 
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1. INTRODUCTION 
The ,&endorphin fragments y-endorphin (&en- 
dorphin-( l- 17)) and a-endorphin @endorphin- 
(1-16)) have originally been identified as opioid 
peptides in an extract of hypothalamic-neurohypo- 
physeal origin (Pitressin Intermediate) [I]. Now, y- 
and a-endorphin have been established as neuro- 
peptides with distinct behavioural and pharma- 
cological activities independent of their opioid 
properties [2-41. The endogenous presence of y- 
endorphin and cY-endorphin in pituitary and brain 
tissue has been indicated in studies using radio- 
receptor assays and immunological methods [5-91 
and more directly demonstrated with combined 
chromatographic and immunological techniques 
[lo-121. However, the chemical nature of these 
peptides has not been elucidated so far. We have 
now achieved the complete characterization of 
native human y-endorphin and cu-endorphin 
purified from single pituitary glands. These data 
demonstrate that y-endorphin and a-endorphin 
are naturally occurring peptides in the human 
pituitary gland. 
2. MATERIALS AND METHODS 
2.1. Extraction procedure 
Two human pituitaries were obtained by autop- 
sy at 7 h and 0.5 h post mortem, frozen on dry ice 
and stored at - 80°C. The pituitary glands were 
extracted separately by boiling in 5 ml of 1 M 
acetic acid for 10 min, cooling to 0°C and 
homogenization in a Teflon-glass homogenizer. 
The homogenate was centrifuged at 15 000 x g, 
for 20 min and the pellet re-extracted with 5 ml of 
1 M acetic acid and centrifuged again. The super- 
r&ants from the two centrifugations were com- 
bined and lyophilized. 
2.2. Gel filtration 
Each lyophilized pituitary extract was 
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reconstituted in 600 pl of 50% (v/v) acetic acid and 
particles were removed by centrifugation at 15 000 
x g,” for 15 min. The clear extract was loaded on 
a Sephadex G-75 superfine column (dimensions 
100 cm x 1.6 cm) in 5Ovo (v/v) acetic acid and 
eluted at a flow rate of 1.5-2.0 ml/h. Fractions of 
about 1 ml were collected and aliquots were taken 
for radioimmunoassay determination. Guided by 
the radioimmunoassay data fractions were pooled 
and dried in vacua at 60°C. 
2.3. High-performance liquid chromatography 
Two HPLC systems based on gradient elution of 
PBondapak Cl8 reverse phase columns (30 cm x 
0.39 cm; 10 gm particle size; Waters Associates) 
were used. Samples in 0.1 M acetic acid, were first 
chromatographed with 10 mM ammonium 
acetate, pH 4.15 (solvent A) and methanol con- 
taining 1.5 ml acetic acid/l (solvent B) in the 
mobile phase. The linear gradient ran from 25 to 
80% B in 55 min with a flow rate of 2.0 ml/min. 
Final purificat .on of peptides was achieved by gra- 
dient elution of a PBondapak Cl8 column with 
0.13% (v/v) heptafluorobutyric acid (HFBA) in 
water (solvent X) and 0.05% (v/v) HFBA in 
methanol (solvent Y). For y-endorphin the gra- 
dient ran from 45 to 55% Y in 10 min; for LY- 
endorphin from 40 to 55% Y in 10 min with a flow 
rate of 1.5 ml/min. In each HPLC step fractions 
of 30 s were collected and aliquots taken for 
radioimmunoassay determination. 
2.4. Amino acid analysis 
Peptide (100-300 pmol) was hydrolyzed in 6 M 
hydrochloric acid containing 0.5% (v/v) 
thioglycollic acid as in [ 131. Amino acid analysis 
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Fig. 1. Gel filtration of a human pituitary extract on Sephadex-G75 superfine and profiles of y-endorphin-like (B) and 
cr-endorphin-like (C) immunoreactive components. (A) shows the profile of UV X’ absorbing material. The arrows 
indicate the elution position of human ,&lipotropin @-LPH-( l-89)) and P-endorphin @3E-( l-3 l)), as determined by a 
radioimmunoassay system for B-endorphin, and of y-[‘*‘I]endorphin. Fraction F4 was used for further purification. 
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was performed by reverse-phase HPLC of o- 
phthaldialdehyde derivatives on a CP-Spher C8 
column (25 cm x 0.46 cm; 7 pm particle size, 
Chrompack), eluted by a gradient of 100 mM 
sodium citrate (pH 6.7) containing 2% (v/v) 
tetrahydrofuran, and methanol [13]. End groups 
were determined by dansylation. 
2.5. Radioimmunoassay systems 
Two separate radioimmunoassay systems for y- 
and a-endorphin, respectively, were used to 
monitor the purification of peptides. The radioim- 
munoassay for y-endorphin employed antiserum 
La which specifically recognized the sequence p- 
endorphin-(9-17) with free COOH-terminus. The 
cross-reaction of antiserum LZ on weight basis was 
8% with a-endorphin and 4% with p- 
endorphin-( l-3 1). In the radioimmunoassay for (Y- 
endorphin antiserum A2 was used, specifically 
recognizing the COOH-terminal sequence p- 
endorphin-(9- 16); cross-reaction with y- 
endorphin was 2% and with ,8-endorphin 1%. 
Details of the specificity of the antisera and of the 
assay procedures have been described [14,15]. 
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Fig.2. Fractionation of fraction F4 by HPLC using ammonium acetate in the mobile phase. (A) UV profile of eluting 
material and elution position of synthetic a-endorphin (WE), y-endorphin (YE) and their W-acetylated forms (AWE, 
AcyE) (B). Distribution of a-endorphin-like (dark area) and y-endorphin-like (open area) immunoreactive peptides. The 
lag time between UV detection and fraction collection was about 10 s. Fraction F4-(Y (tubes 44,459 and F4-y (tubes 
63,64) were subjected to further purification. 
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3. RESULTS Table 1 
Amino acid analysis of native human y-endorphin and 
cu-endorphin isolated from single human pituitary glands Gel filtration on Sephadex G-75 superfine of an 
acid extract of a single human pituitary resulted in 
separation of two y-endorphin immunoreactive 
components with different molecular size and two 
with a-endorphin immunoreactivity (fig. 1). The 
larger y-endorphin immunoreactive component 
(top: fraction 71; fig. 1B) eluted 5 fractions later 
than human ,&-lipotropin-(l-89). The smaller y- 
endorphin immunoreactive form co-eluted with y- 
[“‘I]endorphin. The large a-endorphin im- 
munoreactive component had the top in fraction 
72 (fig.lC), while the smaller component eluted 
slightly later than y-[r2?]endorphin. 
Amino 
acid= 
Peptide F4-y Peptide F4-a 
Fractions 121-126 having the smaller y-endor- 
phin immunoreactive component were pooled 
(coded F4, fig.l), and contained about half of 
the total quantity of the smaller cY-endorphin im- 
munoreactive form. HPLC fractionation of frac- 
tion F4 yielded single peaks of y-endorphin- and cy- 
endorphin-like immunoreactivity (coded F4-y and 
F~-(Y, respectively; fig.2). Final purification of 
peptides F4-y and F4-mu was achieved by HPLC 
with HFBA in the mobile phase (fig.3). The amino 
acid composition and end group of peptides F4-y 
and F4-a indicated the high purity of the isolated 
peptides and demonstrated that they represented 
authentic y-endorphin and a-endorphin, respec- 
tively (table 1). Their identity was in agreement 
with their co-migration with synthetic y- and (Y- 
endorphin in all analytic systems used. 
ASP 
GlU 
Ser 
His 
Arg 
ClY 
Thr 
Ala 
Tyr 
Met 
Val 
Phe 
Ile 
Leu 
Lys 
0.04 0.01 (0) b.d. b.d. 
2.01 1.83 (2) 2.24 2.08 
2.23 1.82 (2) 1.87 1.91 
b.d. b.d. (0) b.d. b.d. 
b.d. b.d. (0) 0.05 b.d. 
1.93 1.87 (2) 2.01 2.13 
2.66 2.96 (3) 2.82 2.81 
0.01 0.01 (0) 0.05 0.05 
1.22 1.22 (1) 1.14 1.09 
0.94 1.03 (1) 0.88 0.93 
1.03 1.09 (1) 1.03 0.95 
0.93 1.03 (1) 1.06 1.05 
0.02 b.d. (0) b.d. b.d. 
2.00 2.18 (2) 0.98 1.06 
1.00 0.96 (1) 1.04 1.11 
(0) 
(2) 
(2) 
(0) 
(0) 
(2) 
(3) 
(0) 
(1) 
(1) 
(1) 
(1) 
(0) 
(1) 
(1) 
End group Tyr Tyr 
Prop- fl-endorphin-(l-17) /3-endorphin-( l- 16) 
osed 
sequence y-endorphin a-endorphin 
a Trp and Pro are not determined by the amino acid 
analysis technique [ 131 
b.d., below detection 
Values represent molar ratios obtained from peptides 
isolated from two individually processed pituitary 
glands. Values in brackets represent he theoretical 
number of residues 
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Fig.3. Final purification of fraction F4y (y-endorphin; 
A) and F4-cr (a-endorphin, B) by HPLC using HFBA in 
the mobile phase. The inset shows the profile of 
immunoreactivity. The arrows indicate the elution 
position of synthetic y-endorphin (A) and a-endorphin 
(B). 
The isolation of y- and a-endorphin was under- 
taken twice and yielded 2.2 nmol y-endorphin and 
0.7 nmol a-endorphin from a human pituitary ob- 
tained 7 h post mortem and 3.0 nmol and 
0.9 nmol, respectively, from a pituitary obtained 
only 0.5 h post mortem as estimated by UV ab- 
sorption of the purified peptide in comparison 
with synthetic peptide. The values of a-endorphin 
represent about half of the maximal yield of cz- 
endorphin due to the cut of fraction F4 (fig.1). 
4. DISCUSSION 
There is considerable evidence for the en- 
dogenous presence of neuropeptides related to y- 
and a-endorphin in rat pituitary and brain. Firstly, 
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opioid peptides with the size of y- and a-endorphin 
have been detected in rat anterior and 
neurointermediate pituitary tissue [5,6]. Secondly, 
using antisera for y- or ru-endorphin, immunoreac- 
tive peptides have been detected by radioim- 
munoassay f7-91 or by immunohistochemical 
techniques (9,16-181. Thirdly, by combining 
radioimmunoassay and HPLC we measured pep- 
tides in rat pituitary and brain with properties in- 
distinguishable from those of authentic y- and cy- 
endorphin [lo-121. Recently, we found that in ad- 
dition to these peptides N”-acetylated y- and CX- 
endorphin are present in the rat neurointermediate 
pituitary and extrahypothalamic brain areas [ 121. 
The characterization of native y-endorphin and a- 
endorphin isolated from human pituitary reported 
here demonstrates the chemical nature of these 
peptides being the free NH2 terminal l-l 7 and 
1-16 sequence of &endorphin, respectively. We 
failed to detect N”-acetylated forms of these pep- 
tides in the HPLC eluate by using radioim- 
munoassays for y- and a-endorphin (fig.2) and a 
radioimmunoassay specifically recognizing the N”- 
acetylated terminus of endorphins (antiserum Nan- 
cy Beth 51, donated by Drs Watson and Akil). 
Thus, we conclude that y- and tu-endorphin with 
free NH2 termini are naturally occurring fragments 
of &endorphin in the human pituitary gland. 
Biological activities of y- and ~-endorphins in the 
central nervous system have been demonstrated 
12-41. The y-endorphin isolated here is biological- 
ly active in a behavioural test (not shown). 
However, the physiological significance of these 
peptides in the human pituitary remains unknown 
as yet. 
digestion of the large y-endorphin immunoreactive 
component we isolated and identified the tryptic 
fragment ,&endorphin-( lo- 17). The specificity of 
antiserum L2 for the free COOH terminal sequence 
&-endorphin-(9-17) and the isolation of ,& 
endorphin-(10-17) demonstrates that this large 
form contains&endorphin-(10-17) as COOH ter- 
minal sequence. The data indicate that this compo- 
nent is human ,&lipotropin-( i-75). Indeed, forma- 
tion of its porcine equivalent &lipotropin-( l-77) 
by a porcine anterior pituitary homogenate has 
been reported [ZO]. 
Similarly, the cu-endorphin-like immunoreactive 
component might represent human fi- 
lipotropin-(l-74). Assuming approximately equal 
cross-reaction in the radioimmunoassay systems, 
the molar quantities of these peptides exceed those 
of y- and a-endorphin about IO-fold. A similar 
ratio for 8-lipotropin-(l-89) and ,&endorphin ex- 
ists in the anterior pituitary 15,211. This suggests 
that in the human pituitary ,&lipotropin-( l-75) 
and -(l-74) serve as precursors for LY- and y- 
endorphin, respectively. Alternatively, ty- and y- 
endorphin could be produced directly from ,& 
endorphin by proteolytic processing 122,231. 
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